Trial Profile
Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): "The CyBorD-DARA Study"
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CyBorD-Dara
- 01 Nov 2022 Results investigating the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma published in the Clinical Lymphoma, Myeloma & Leukemia
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Dec 2018 Results assessing safety and efficacy of Daratumumab in Multiple myeloma patients presented at the 60th Annual Meeting and Exposition of the American Society of Hematology